These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 5565858)

  • 61. [Polygraphic study of nocturnal sleep in Parkinsonian syndromes. Effects of treatment levo-dopa].
    Muratorio A; Murri L; Cerone G
    Riv Neurobiol; 1970; 16(4):361-76. PubMed ID: 4350093
    [No Abstract]   [Full Text] [Related]  

  • 62. [Effects of L-dopa and stereotaxic surgery in Parkinsonism].
    Sugita K; Mutsuga N; Takaoka Y; Takeda A
    No To Shinkei; 1970 Sep; 22(9):1103-8. PubMed ID: 4918927
    [No Abstract]   [Full Text] [Related]  

  • 63. L-DOPA suppression of thyrotropin-releasing hormone response in man.
    Spaulding SW; Burrow GN; Donabedian R; van Woert M
    J Clin Endocrinol Metab; 1972 Jul; 35(1):182-5. PubMed ID: 4624348
    [No Abstract]   [Full Text] [Related]  

  • 64. [Evaluation of L-DOPA in Parkinsonism with special reference to the study by double-blind method].
    Okajima T; Kubota A; Nakahara N; Takeda S; Shimomura K
    Naika; 1972; 29(2):335-43. PubMed ID: 4552443
    [No Abstract]   [Full Text] [Related]  

  • 65. [Treatment of Parkinsonism with L-dopa--with special reference to clinical effects, side effects and urinary metabolites of catecholamines].
    Uono M; Tanabe H; Yano Y; Nakao K
    No To Shinkei; 1970 Sep; 22(9):1091-101. PubMed ID: 5536082
    [No Abstract]   [Full Text] [Related]  

  • 66. [Action of amantadine HCl alone and in combination with L-dopa on parkinsonism].
    Danielczyk W; Korten JJ
    Med Monatsschr; 1971 Oct; 25(10):472-9. PubMed ID: 5122447
    [No Abstract]   [Full Text] [Related]  

  • 67. Effect of L-dopa on the seborrhoea of Parkinsonism.
    Burton JL; Cartlidge M; Shuster S
    Br J Dermatol; 1973 May; 88(5):475-9. PubMed ID: 4268445
    [No Abstract]   [Full Text] [Related]  

  • 68. L-dopa for parkinsonism.
    Reveno WS; Bauer RB; Rosenbaum H
    Geriatrics; 1973 Jan; 28(1):86-8. PubMed ID: 4683093
    [No Abstract]   [Full Text] [Related]  

  • 69. [Effect of the combined treatment of Parkinson patients with L-Dopa and a decarboxylase inhibitor (Ro4-4602). Quantitative analysis of bradykinesia by means of reaction time measurements].
    Kaufmann W; Butz P; Wiesendanger M
    Dtsch Z Nervenheilkd; 1970; 197(1):85-100. PubMed ID: 5522871
    [No Abstract]   [Full Text] [Related]  

  • 70. [Habituation of trigemino-facial reflexes in parkinsonism treated with L-DOPA].
    Messina C
    Riv Neurol; 1970; 40(5):327-36. PubMed ID: 5507461
    [No Abstract]   [Full Text] [Related]  

  • 71. Electroencephalographic changes occurring during L-dopa treatment.
    Herman MN; Rowan AJ; Goldensohn ES
    Trans Am Neurol Assoc; 1971; 96():252-4. PubMed ID: 5159096
    [No Abstract]   [Full Text] [Related]  

  • 72. [Changes in nocturnal sleep in parkinsonism patients treated with L-dopa].
    Bricolo A; Turella G; Mazza CA; Buffatti P; Grosslercher JC
    Sist Nerv; 1970; 22(2):181-90. PubMed ID: 4323416
    [No Abstract]   [Full Text] [Related]  

  • 73. [Parkinsonism. Therapeutic, pathophysiological, pharmacological and biochemical aspects].
    Dupont E
    Ugeskr Laeger; 1973 Jan; 135(3):116-22. PubMed ID: 4567942
    [No Abstract]   [Full Text] [Related]  

  • 74. [Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor].
    Stammler A; Vielhaber K
    Fortschr Neurol Psychiatr Grenzgeb; 1972 Oct; 40(10):564-8. PubMed ID: 4565521
    [No Abstract]   [Full Text] [Related]  

  • 75. [The Rey complex picture test in evaluation of some effects induced by treatment with L-dopa in patients with parkinsonism].
    Megna GF; Puca FM; Micalizzi V; Leggiadro N; Di Rosa AE
    Acta Neurol (Napoli); 1971; 26(4):473-83. PubMed ID: 4943712
    [No Abstract]   [Full Text] [Related]  

  • 76. Some quantitative behavioral changes in L-dopa therapy.
    Meier MJ; Baker AB; Martin WE
    Geriatrics; 1972 Jun; 27(6):89-97. PubMed ID: 5032486
    [No Abstract]   [Full Text] [Related]  

  • 77. Sexual function and affect in parkinsonian men treated with L-dopa.
    Brown E; Brown GM; Kofman O; Quarrington B
    Am J Psychiatry; 1978 Dec; 135(12):1552-5. PubMed ID: 717578
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Case of parkinsonism with remission of symptoms by the administration of L-DOPA].
    Tsuyuzaki K; Onai M; Uehara A; Shimojo H; Sudo H
    Naika; 1970 Nov; 26(5):986-8. PubMed ID: 5478157
    [No Abstract]   [Full Text] [Related]  

  • 79. [Psychiatric complications of L-Dopa treatment of parkinsonism].
    Refsum H
    Tidsskr Nor Laegeforen; 1973 Apr; 93(10):680-5. PubMed ID: 4755082
    [No Abstract]   [Full Text] [Related]  

  • 80. [Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association].
    Wajsbort J; Hemli JA; Alfandary I; Yahel M; Siegfried J
    Wien Med Wochenschr; 1971 Oct; 121(42):741-5. PubMed ID: 5115985
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.